as suspected not black and white outcome which is typical for...

as suspected not black and white outcome which is typical for trials data

but the key will be if TGA accepts the data for schedule 3 being granted - then it is a completely different ball game as all CND currently prescribed under Special Access Scheme for insomnia will not be able to be supplied - the Schedule 3 BOD product would be only product that can be supplied and that would be over the counter at any chemist so that would be a big outcome.

smy read is still in the game and way further down track it seems than competitors - if value of schedule 3 is X and it has been discounted significantly to date, then that discount has to change on back of these findings and stock should re-rate up to reflect lower discount to potential ,commercialisation value .....